Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186381 | 1.00 | MAPT (0.60) | MAPTALDH1A1LMNASMN1; SMN2NR1H2 | |
| SCHEMBL18186372 | 1.00 | MAPT (0.60) | MAPTALDH1A1LMNASMN1; SMN2NR1H2 | |
| SCHEMBL18186345 | 0.89 | MAPT (0.63) | MAPTALDH1A1LMNASMN1; SMN2NR1H2 | |
| SCHEMBL16569974 | 0.89 | MAPT (0.63) | MAPTALDH1A1LMNASMN1; SMN2NR1H2 | |
| SCHEMBL17645014 | 0.89 | MAPT (0.63) | MAPTALDH1A1LMNASMN1; SMN2NR1H2 | |
| SCHEMBL16569609 | 0.89 | MAPT (0.63) | MAPTALDH1A1LMNASMN1; SMN2NR1H2 | |
| SCHEMBL27979420 | 0.86 | MAPT (0.58) | MAPTALDH1A1LMNASMN1; SMN2NR1H2 | |
| SCHEMBL18186339 | 0.85 | NR1H2 (0.47) | MAPTALDH1A1LMNANR1H2NR1H3 | |
| SCHEMBL16824946 | 0.85 | NR1H2 (0.47) | MAPTALDH1A1LMNANR1H2NR1H3 | |
| SCHEMBL18186231 | 0.85 | NR1H2 (0.47) | MAPTALDH1A1LMNANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | MAPT 3728/4885ALDH1A1 1940/4885LMNA 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.